NASDAQ:AVXL - Anavex Life Sciences Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $3.16 -0.05 (-1.56 %) (As of 07/22/2018 04:00 PM ET)Previous Close$3.16Today's Range$3.14 - $3.2452-Week Range$1.85 - $5.15Volume158,655 shsAverage Volume1.20 million shsMarket Capitalization$141.13 millionP/E Ratio-9.58Dividend YieldN/ABeta0.96 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. Its preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York. Receive AVXL News and Ratings via Email Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolNASDAQ:AVXL CUSIPN/A Webwww.anavex.com Phone844-689-3939 Debt Debt-to-Equity RatioN/A Current Ratio7.57 Quick Ratio7.57 Price-To-Earnings Trailing P/E Ratio-9.58 Forward P/E Ratio-8.10 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.58 per share Price / Book5.45 Profitability EPS (Most Recent Fiscal Year)($0.33) Net Income$-13,460,000.00 Net MarginsN/A Return on Equity-73.46% Return on Assets-65.73% Miscellaneous Employees10 Outstanding Shares44,660,000Market Cap$141.13 Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions What is Anavex Life Sciences' stock symbol? Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL." How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp (NASDAQ:AVXL) released its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. View Anavex Life Sciences' Earnings History. When is Anavex Life Sciences' next earnings date? Anavex Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Anavex Life Sciences. What price target have analysts set for AVXL? 4 brokerages have issued 1-year target prices for Anavex Life Sciences' shares. Their forecasts range from $6.00 to $10.00. On average, they expect Anavex Life Sciences' stock price to reach $7.50 in the next year. This suggests a possible upside of 137.3% from the stock's current price. View Analyst Ratings for Anavex Life Sciences. What is the consensus analysts' recommendation for Anavex Life Sciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Anavex Life Sciences stock? Here are some recent quotes from research analysts about Anavex Life Sciences stock: 1. According to Zacks Investment Research, "ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. " (7/11/2018) 2. Maxim Group analysts commented, "We have increased our therapeutic rate cut in our model to 90%, from 75% – taking our price target to $5, from $14, which is still substantially higher versus the current stock price – due to a combination of factors which include: ○ The trial was delayed (biomarkers) and will take time and money. While the company has $28M in capital today, we believe a lot more capital will be needed as the next phases of clinical development get underway, ○ When will we see meaningful clinical data that can convince both KOL’s and Industry experts that the company may have a drug? It will take time." (2/8/2018) Who are some of Anavex Life Sciences' key competitors? Some companies that are related to Anavex Life Sciences include Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Protalex (PRTX), Bioanalytical Systems (BASI), US Stem Cell (USRM), Tenax Therapeutics (TENX) and Geovax Labs (GOVX). Who are Anavex Life Sciences' key executives? Anavex Life Sciences' management team includes the folowing people: Dr. Christopher U. Missling, Chairman, Pres, CEO & Sec. (Age 52)Ms. Sandra Boenisch, Principal Financial Officer & Treasurer (Age 37)Mr. Stephan Toutain, Sr. VP of Operations (Age 52)Dr. Emmanuel O. Fadiran RPh, Ph.D., Sr. VP of Regulatory AffairsDr. Daniel Klamer, VP of Bus. Devel. & Scientific Strategy Has Anavex Life Sciences been receiving favorable news coverage? News articles about AVXL stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anavex Life Sciences earned a media sentiment score of 0.09 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.92 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. How do I buy shares of Anavex Life Sciences? Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Anavex Life Sciences' stock price today? One share of AVXL stock can currently be purchased for approximately $3.16. How big of a company is Anavex Life Sciences? Anavex Life Sciences has a market capitalization of $141.13 million. The biotechnology company earns $-13,460,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Anavex Life Sciences employs 10 workers across the globe. How can I contact Anavex Life Sciences? Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected] MarketBeat Community Rating for Anavex Life Sciences (NASDAQ AVXL)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 231 (Vote Outperform)Underperform Votes: 122 (Vote Underperform)Total Votes: 353MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences and other stocks. Vote "Outperform" if you believe AVXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?